What is O2M Technologies?
O2M Technologies operates at the intersection of biophysics and clinical diagnostics, specializing in the development of patented oxygen imaging technology. The firm's flagship JIVA-25 preclinical oxygen imager provides high-resolution, three-dimensional partial oxygen pressure (pO2) maps, which are critical for understanding tumor microenvironments and metabolic processes. Beyond hardware, the company provides specialized contract research services, facilitating both in vitro and in vivo studies for pharmaceutical and academic partners. This dual-revenue model allows O2M to maintain a robust presence in cancer research and drug development, where precise oxygen distribution data is increasingly viewed as a vital biomarker for therapeutic efficacy.
How much funding has O2M Technologies raised?
O2M Technologies has raised a total of $81K across 1 funding round:
Debt
$81K
Debt (2021): $81K with participation from PPP
Key Investors in O2M Technologies
PPP
Public-Private Partnership
What's next for O2M Technologies?
With the recent influx of capital, O2M Technologies is well-positioned to scale its operational footprint and accelerate the commercialization of its imaging platforms. The strategic focus will likely shift toward expanding the utility of its pO2 mapping technology within clinical diagnostic workflows, potentially moving from preclinical research environments into broader translational medicine applications. As the company matures through its current growth stage, investors will be monitoring the integration of its oxygen measurement solutions into standard drug development pipelines, which could significantly enhance the firm's market valuation and long-term competitive advantage in the life sciences sector.
See full O2M Technologies company page
